基于凝血因子Ⅺ的血栓防治新药研究进展  

Research Progress on New Drugs for Thrombosis Prevention and Treatment Based on Coagulation FactorⅪ

作　　者：雷洋 边原[1] 廖健婷 李刚[1] 武刘芸 郑星月 李炼 韩丽珠 尹琪楠 LEI Yang;BIAN Yuan;LIAO Jianting;LI Gang;WU Liuyun;ZHENG Xingyue;LI Lian;HAN Lizhu;YIN Qinan(Department of Pharmacy,Sichuan Academy of Medical Sciences,Sichuan Provincial People's Hospital,Chengdu 610072,China;College of Medicine,University of Electronic Science and Technology of China,Sichuan Provincial Key Laboratory of Individualized Medicine,Chengdu 610072,China)

机构地区：[1]四川省医学科学院·四川省人民医院药学部,成都610072 [2]电子科技大学医学院,个体化药物治疗四川省重点实验室,成都610072

出　　处：《医药导报》2025年第3期452-458,共7页Herald of Medicine

基　　金：国家重点研发计划(2020YFC2005506);四川省科技厅自然科学基金资助项目(2022NSFSC0818);中国药学会医院药学专委会医院药学科研专项(青年项目:CPA-Z05-ZC-2023-002);中华国际医学交流基金会(面上项目:Z-2021-46-2101-2023);中国研究型医院学会科研专项(Y2022FH-YWPJ01-202)。

摘　　要：抗凝药物在预防和治疗血栓栓塞方面应用广泛。现有抗凝药具有拮抗或阻断凝血级联关键步骤的共同特点,同时也会增加出血风险。研究表明,Ⅺ因子抑制剂是一种可能平衡血栓与出血的药物。近年来,反义寡核苷酸、靶向Ⅺ因子的单克隆抗体、小分子抑制剂、天然抑制剂和核酸适配体等Ⅺ因子抑制剂作为潜在的可开发抗凝药物被广泛研究。研究结果也表明,Ⅺ因子抑制剂在保障抗凝有效性的同时可以降低出血风险,其对终末期肾脏病血栓、非心源性栓塞性卒中、急性冠脉综合征等患者人群的血栓防治具有一定潜力。该文围绕Ⅺ因子抑制剂作用机制、药物类别、药理学特点以及临床研究进展等进行综述,以期为研发新的抗凝药物以及临床抗凝治疗提供思路。Anticoagulants are widely used in the prevention and treatment of thromboembolism.Existing anticoagulants share the common feature of antagonizing or blocking critical steps in the coagulation cascade,which also increases the risk of bleeding.Studies have indicated that factorⅪinhibitors represent a potential therapeutic option for balancing thrombosis and bleeding risks.In recent years,various factorⅪinhibitors,including antisense oligonucleotides(ASOs),monoclonal antibodies,synthetic small molecules,natural peptides,and aptamers,have been extensively researched as potentially exploitable anticoagulants.Research findings also suggest that factorⅪinhibitors can reduce bleeding risks while ensuring anticoagulant efficacy,exhibiting potential for thrombosis prevention and treatment in patient populations such as those with end-stage renal disease,non-cardioembolic ischemic stroke,and acute coronary syndrome.This article reviewed the mechanisms of action,drug classes,pharmacological characteristics,and clinical research progress of factorⅪinhibitors,aiming to provide insights into the development of new anticoagulants and clinical anticoagulant therapies.

关 键 词：凝血因子Ⅺ 抗凝药物 血栓 出血 

分 类 号：R973.1[医药卫生—药品]